← Back to Search

POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study (PORTEND Trial)

N/A
Waitlist Available
Research Sponsored by ZS Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 days
Awards & highlights
No Placebo-Only Group

Summary

This study assesses serum potassium and cardiac rhythm trends in subjects with end stage renal disease (ESRD) who are on 3 times weekly maintenance hemodialysis for at least 60 days. Dialysate K (relative potassium concentration in dialysate) must be stable for 2 weeks prior to enrollment.The number of subjects on 3K or higher dialysate will be limited to 60, with the remainder of the subjects on 1K or 2K dialysate.

Eligible Conditions
  • Hyperkalemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients
Secondary study objectives
Incidence of Cardiac Arrhythmias
Incidence of Pre-dialysis Hyperkalemia (HK) After the Long Inter-dialytic Period (LIDP) in Patients on ≥3K Dialysate.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cardiac rhythm remote monitoring systemExperimental Treatment1 Intervention
Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac rhythm remote monitoring system
2015
N/A
~240

Find a Location

Who is running the clinical trial?

ZS Pharma, Inc.Lead Sponsor
7 Previous Clinical Trials
2,211 Total Patients Enrolled
7 Trials studying Hyperkalemia
2,211 Patients Enrolled for Hyperkalemia
Henrik Rasmussen, MD, PhDStudy ChairZS Pharma, Inc.
9 Previous Clinical Trials
2,014 Total Patients Enrolled
4 Trials studying Hyperkalemia
1,335 Patients Enrolled for Hyperkalemia
~24 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top